Molecular Approaches To Target GPCRs in Cancer Therapy
AbstractHundreds of G protein coupled receptor (GPCR) isotypes integrate and coordinate the function of individual cells mediating signaling between different organs in our bodies. As an aberration of the normal relationships that organize cells’ coexistence, cancer has to deceive cell-cell communication in order to grow and spread. GPCRs play a critical role in this process. Despite the fact that GPCRs represent one of the most common drug targets, current medical practice includes only a few anticancer compounds directly acting on their signaling. Many approaches can be envisaged to target GPCRs involved in oncology. Beyond interfering with GPCRs signaling by using agonists or antagonists to prevent cell proliferation, favor apoptosis, induce maturation, prevent migration, etc., the high specificity of the interaction between the receptors and their ligands can be exploited to deliver toxins, antineoplastic drugs or isotopes to transformed cells. In this review we describe the strategies that are in use, or appear promising, to act directly on GPCRs in the fight against neoplastic transformation and tumor progression. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Innamorati, G.; Valenti, M.T.; Giovinazzo, F.; Dalle Carbonare, L.; Parenti, M.; Bassi, C. Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4, 567-589.
Innamorati G, Valenti MT, Giovinazzo F, Dalle Carbonare L, Parenti M, Bassi C. Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals. 2011; 4(4):567-589.Chicago/Turabian Style
Innamorati, Giulio; Valenti, Maria Teresa; Giovinazzo, Francesco; Dalle Carbonare, Luca; Parenti, Marco; Bassi, Claudio. 2011. "Molecular Approaches To Target GPCRs in Cancer Therapy." Pharmaceuticals 4, no. 4: 567-589.